Where the Revenue growth came from
OptiBiotix Health plc (LSE:OPTI) reported higher revenue for the first half of 2026, but the growth did not come evenly from its markets. The interim figures show a Business increasingly reliant on Asian customers for its SlimBiome weight-management ingredient, while sales in India slowed sharply. How the company achieved that growth, and what it cost elsewhere in the accounts, is the focus here.
The business in brief
OptiBiotix, quoted on AIM under the code OPTI, develops and sells microbiome-focused ingredients and products. Its main commercial ingredient is SlimBiome, used in weight-management products sold by partners, alongside WellBiome. It is also developing SweetBiotix, a second-generation fibre-based sweetener, and holds investments in other listed companies, including an associate stake in ProBiotix Health and shares in SkinBioTherapeutics. Revenue comes from ingredient sales, licensing and its own consumer products.
The interim report
On 17 September 2026, the company published its half-year financial report for the six months to 30 June 2026. It reported revenue of £679,000, up from £557,000 a year earlier, an increase of around 22%. Gross Profit rose to £380,000 from £303,000, lifting gross Margin to 55.9% from 54.4%.
The regional split explains the improvement. Rest of World sales rose 133% to £333,000 and accounted for 49% of group revenue. The company pointed to Demand across Asian markets including Vietnam, Indonesia, Taiwan, Malaysia, the Philippines and Thailand, and said it had delivered 12 tonnes of SlimBiome to a partner in Taiwan. UK and European revenue was £316,000, while India contributed just £3,000. OptiBiotix linked the weakness in India to the availability of generic GLP-1 medicines after Patent expiry. It also said it had suspended a trading Partnership in China.
Costs, losses and the balance sheet
Cost control also helped. Selling costs fell 69.5% to £76,000, and R&D and patent costs declined to £90,000. The operating loss narrowed to £753,000 from £1.44 million. However, the loss before tax widened to £1.60 million from £1.18 million. The report shows this was driven by a £554,000 loss on disposal of investments and a £320,000 Fair Value loss on investments, partly offset by a £29,000 share of profit from its associate.
Cash was £989,000 at 30 June 2026, compared with £1.04 million at the end of 2025. Net Assets fell to £4.73 million from £8.42 million a year earlier, reflecting the lower value of its Investment portfolio. The company described its Balance Sheet as debt-free.
After the period, OptiBiotix said it had signed a Trademark licence with a large, unnamed US corporate to launch SlimBiome-containing products in the USA, and another with a major direct-selling company to expand in India. On 15 September 2026 it appointed Imad Farhat, a former Givaudan and dsm-firmenich executive, as a non-executive director of its Subsidiary OptiBiotix Ltd to support SweetBiotix commercialisation.
Risks to consider
The revenue base remains small, so individual partner orders can move the numbers significantly. The concentration in Asia brings exposure to a handful of distributors, and the decline in India shows how changes in the wider weight-loss market can affect demand. Investment values have already reduced net assets, and further movements in those holdings could do so again. Cash of under £1 million also leaves limited headroom if progress is slow. SweetBiotix has yet to generate meaningful revenue, and the new US and Indian licences are not yet reflected in sales.
The answer
OptiBiotix lifted first-half revenue mainly by selling more SlimBiome into Asian markets, while trimming selling and R&D costs to halve its operating loss. Those gains were offset at the pre-tax level by investment disposal and valuation losses. The licensing agreements announced after the period suggest the company is seeking broader distribution, but whether they translate into sustained revenue remains to be seen.






Please wait processing your request...